Published in Proc Natl Acad Sci U S A on June 06, 2000
Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol (2008) 1.46
Improving cancer chemotherapy with modulators of ABC drug transporters. Curr Drug Targets (2011) 1.35
Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci U S A (2000) 1.34
Activation of the growth-differentiation factor 11 gene by the histone deacetylase (HDAC) inhibitor trichostatin A and repression by HDAC3. Mol Cell Biol (2004) 1.26
Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. Br J Cancer (2014) 1.11
Cancer wars: natural products strike back. Front Chem (2014) 1.11
Pregnane X receptor and natural products: beyond drug-drug interactions. Expert Opin Drug Metab Toxicol (2006) 1.01
Mechanism targeted discovery of antitumor marine natural products. Curr Med Chem (2004) 0.95
Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin. Clin Cancer Res (2008) 0.91
Adding pharmacogenomics to the development of new marine-derived anticancer agents. J Transl Med (2006) 0.90
DNA and the chromosome - varied targets for chemotherapy. Cell Chromosome (2004) 0.88
Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients. Sarcoma (2006) 0.86
Role of trabectedin in the treatment of soft tissue sarcoma. Onco Targets Ther (2009) 0.86
Educational paper. The development of new therapies for pediatric oncology. Eur J Pediatr (2010) 0.86
Reversing multidrug resistance by RNA interference through the suppression of MDR1 gene in human hepatoma cells. World J Gastroenterol (2006) 0.81
Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype. Invest New Drugs (2007) 0.79
Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice. Invest New Drugs (2009) 0.79
Inhibitory effects of marine-derived DNA-binding anti-tumour tetrahydroisoquinolines on the Fanconi anaemia pathway. Br J Pharmacol (2013) 0.78
Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer. Invest New Drugs (2005) 0.78
Protein Recognition in Drug-Induced DNA Alkylation: When the Moonlight Protein GAPDH Meets S23906-1/DNA Minor Groove Adducts. Int J Mol Sci (2015) 0.77
Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin. Br J Cancer (2015) 0.77
Trabectedin for advanced soft tissue sarcomas: optimizing use. Ther Clin Risk Manag (2014) 0.75
Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line. Oncotarget (2016) 0.75
Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics. Nat Prod Rep (2015) 0.75
Effect of the novel antipsychotic drug perospirone on P-glycoprotein function and expression in Caco-2 cells. Eur J Clin Pharmacol (2008) 0.75
Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem (1990) 9.21
The 400 kDa subunit of the PCAF histone acetylase complex belongs to the ATM superfamily. Mol Cell (1998) 2.08
Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol Cell Biol (1998) 2.05
Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res (1999) 1.91
Xenopus NF-Y pre-sets chromatin to potentiate p300 and acetylation-responsive transcription from the Xenopus hsp70 promoter in vivo. EMBO J (1998) 1.85
DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry (1996) 1.73
P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood (1999) 1.61
The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci U S A (1998) 1.60
Light scatter of isolated cell nuclei as a parameter discriminating the cell-cycle subcompartments. Methods Cell Biol (1994) 1.50
Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem (1999) 1.48
Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci U S A (2000) 1.34
Transcriptional activation of the MDR1 gene by UV irradiation. Role of NF-Y and Sp1. J Biol Chem (2000) 1.27
Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res (1998) 1.21
In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol (1998) 1.14
P-glycoproteins: mediators of multidrug resistance. Semin Cell Biol (1993) 1.11
Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743. Proc Natl Acad Sci U S A (1999) 1.04
Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove. Proc Natl Acad Sci U S A (1999) 1.01
Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, MDR1/P-glycoprotein, in drug-selected cell lines and patients with drug refractory ALL. Genes Chromosomes Cancer (1998) 0.99
Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. Anticancer Drug Des (1999) 0.94
Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia. Blood (1999) 0.88
Characterisation of antimitotic products from marine organisms that disorganise the microtubule network: ecteinascidin 743, isohomohalichondrin-B and LL-15. Br J Cancer (1996) 0.86
Amplification and expression of genes associated with multidrug resistance in mammalian cells. Science (1986) 2.34
Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol Cell Biol (1998) 2.05
Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res (1999) 1.91
In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors. comparison with the clinical results. Eur J Cancer (2002) 1.48
Transcriptional repression by p53 through direct binding to a novel DNA element. J Biol Chem (2001) 1.35
Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci U S A (2000) 1.34
Dihydrofolate reductase protein inhibits its own translation by binding to dihydrofolate reductase mRNA sequences within the coding region. Biochemistry (1997) 1.30
A conserved downstream element defines a new class of RNA polymerase II promoters. J Biol Chem (1995) 1.28
Transcriptional activation of the MDR1 gene by UV irradiation. Role of NF-Y and Sp1. J Biol Chem (2000) 1.27
The marine compound spisulosine, an inhibitor of cell proliferation, promotes the disassembly of actin stress fibers. Cancer Lett (2000) 1.23
Phenotypic expression in Escherichia coli and nucleotide sequence of two Chinese hamster lung cell cDNAs encoding different dihydrofolate reductases. Mol Cell Biol (1984) 1.21
Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res (1998) 1.21
In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol (1998) 1.14
Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res (2001) 1.10
Association of sorcin with the cardiac ryanodine receptor. J Biol Chem (1995) 1.09
Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res (2001) 1.07
Structure--activity relationships of the didemnins. J Med Chem (1996) 1.05
The marine sphingolipid-derived compound ES 285 triggers an atypical cell death pathway. Apoptosis (2007) 1.04
Antifolate-resistant Chinese Hamster Cells. mRNA directed overproduction of multiple dihydrofolate reductases from a series of independently derived sublines containing amplified dihydrofolate reductase genes. J Biol Chem (1982) 1.03
Mode of action of thiocoraline, a natural marine compound with anti-tumour activity. Br J Cancer (1999) 1.00
Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. Anticancer Drug Des (1999) 0.94
Translational regulation of the synthesis of dihydrofolate reductase. Adv Exp Med Biol (1993) 0.94
Chromosomal organization of amplified genes in multidrug-resistant Chinese hamster cells. Cancer Res (1988) 0.92
Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine. Br J Cancer (2002) 0.91
Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743). Br J Cancer (2000) 0.83
In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743). Ann Oncol (1998) 0.82
Stable transfection of the P-glycoprotein promoter reproduces the endogenous overexpression phenotype: the role of MED-1. Cancer Res (1996) 0.81
The effects of serum depletion and dexamethasone on growth and differentiation of human neuroblastoma cell lines. J Pediatr Surg (2000) 0.79
Cell cycle perturbations and apoptosis induced by isohomohalichondrin B (IHB), a natural marine compound. Br J Cancer (1999) 0.79
In vitro hematotoxicity of Aplidine on human bone marrow and cord blood progenitor cells. Toxicol In Vitro (2001) 0.78
Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J Mass Spectrom (1998) 0.78
Optimization of a versatile in vitro transcription assay for the expression of multiple start site TATA-less promoters. Biochemistry (2001) 0.78
Bioanalysis of aplidine, a new marine antitumoral depsipeptide, in plasma by high-performance liquid chromatography after derivatization with trans-4-hydrazino-2-stilbazole. J Chromatogr B Biomed Sci Appl (1999) 0.77
P-glycoprotein content and mediation of vincristine efflux: correlation with the level of differentiation in luminal epithelium of mouse small intestine. Cancer Commun (1991) 0.76
Intracellular metabolism of hCG. Ann Endocrinol (Paris) (1984) 0.75
Studies on the expression of the amplified domain in human neuroblastoma cells. Prog Clin Biol Res (1985) 0.75
Analysis of Ecteinascidin 743, a new potent marine-derived anticancer drug, in human plasma by high-performance liquid chromatography in combination with solid-phase extraction. J Chromatogr B Biomed Sci Appl (1998) 0.75
Bioanalysis of thiocoraline, a new marine antitumoral depsipeptide, in plasma by high-performance liquid chromatography and fluorescence detection. J Chromatogr B Biomed Sci Appl (1999) 0.75